Please login to the form below

Not currently logged in
Email:
Password:

MSD

This page shows the latest MSD news and features for those working in and with pharma, biotech and healthcare.

MSD’s Keytruda scores another EU okay, in head and neck cancer

MSD’s Keytruda scores another EU okay, in head and neck cancer

First anti-PD-1 drug to improve overall survival in first-line setting. The EMA has approved Merck &Co/MSD’s Keytruda as a first-line treatment for head and neck ... new treatment option and MSD’s drug another leg up over its rivals in the checkpoint

Latest news

More from news
Approximately 54 fully matching, plus 335 partially matching documents found.

Latest Intelligence

  • The first, my last, my everything The first, my last, my everything

    It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Last month, Johnson &Johnson Innovation, Takeda and Evotec became the latest pharma research groups to join the initiative, alongside existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    Moreover, it’s multi-funded by BMS, Amgen, MSD and J&J to identify inefficiencies and collaboratively develop benchmarks or tools to improve resource allocations towards what matters most to patients,

More from intelligence
Approximately 4 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 47 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...

Infographics